| 2401BT-002P | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma | Not Open |
| ACNS0332 | Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients | Open |
| ACNS0831 | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with
Newly Diagnosed Ependymoma Ages 1 to 21 years | Open |
| ACNS1422 | A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients | Open |
| ACNS1721 | A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations | Open |
| ANBL1221 | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma | Open |
| ANBL1232 | Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| EF-25 | Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | Open |
| ETCTN10186-CIRB | A Phase I/II Study of Nivolumab plus of minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma | Open |
| LCCC1743-ATL | A Phase I Study of Autologous Activated T-cells expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients with Relapsed or Refractory Neuroblastoma | Open |
| LCCC1844 | MR Imaging Biomarkers for Radiation-induced Neurocognitive Decline
Following Stereotactic Radiosurgery of Newly Diagnosed Brain Metastases: An
Observational Pilot Study | Open |
| MIBG-EXPANDED-ACCESS | An Open Label, Expanded Access Protocol Using 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy In Patients With Refractory Neuroblastoma, Pheochromocytoma, Or Paraganglioma | Open |
| ML28897PRO/02 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents. | Open |
| NANT15-02/LORLATINIB | Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma | Open |
| NANT17-01/MIBG-D | A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma | Open |
| NC-6300-001 | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | Open |
| NRG-BN003 | Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma | Open |
| OT-15-001 | A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
| Open |
| SGNTV-001 | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. | Open |